{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:10:47Z","timestamp":1793913047551,"version":"4.8.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T00:00:00Z","timestamp":1652227200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T00:00:00Z","timestamp":1652227200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001775","name":"University of Technology Sydney","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001775","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:title>Opinion statement<\/jats:title><jats:p>Delirium is a common medical complication in people living with cancer, particularly with more advanced disease. Delirium is associated with significant symptom burden which causes distress and impacts quality of life. As recommended by international guidelines, a high degree of suspicion is needed to ensure delirium is detected early. Attention to collateral history can provide clues to changes in cognition and attention. Non-pharmacological approaches that can be considered essential elements of care are effective in reducing the risk of delirium. Delirium screening using a validated measure is recommended as even expert clinicians can underdiagnose or miss delirium. The diagnostic assessment requires consideration of the cancer diagnosis and comorbidities, in the context of potential reversibility, goals of care, and patient preferences. The gold standard approach based on expert consensus is to institute management for delirium precipitants supported by non-pharmacological essential care, with the support of an interdisciplinary team. Medication management should be used sparingly and for a limited period of time wherever possible for severe perceptual disturbance or agitation which has not improved with non-pharmacological approaches. Clinicians should be familiar with the registered indication for medications and seek informed consent for off-label use. All interventions put in place to manage delirium need to consider net clinical benefit, including harms such as sedation and loss of capacity for meaningful interaction. Clear communication and explanation are needed regularly, with the person with delirium as far as possible and with surrogate decision makers. Delirium can herald a poor prognosis and this needs to be considered and be discussed as appropriate in shared decision-making. Recall after delirium has resolved is common, and opportunity to talk about this experience and the related distress should be offered during the period after recovery.<\/jats:p>","DOI":"10.1007\/s11864-022-00987-9","type":"journal-article","created":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T05:10:25Z","timestamp":1652245825000},"page":"951-960","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The Dilemma of Treating Delirium: the Conundrum of Drug Management"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6756-6119","authenticated-orcid":false,"given":"Meera R.","family":"Agar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Amgarth-Duff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,11]]},"reference":[{"key":"987_CR1","doi-asserted-by":"crossref","unstructured":"\u2022 Watt CL, Momoli F, Ansari MT, et al. The incidence and prevalence of delirium across palliative care settings: a systematic review. Palliat Med 2019; 33: 865-877. Provides a summary of the key epidemiological data for delirium in palliative care.","DOI":"10.1177\/0269216319854944"},{"key":"987_CR2","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12904-020-00668-0","volume":"19","author":"E-J Shim","year":"2020","unstructured":"Shim E-J, Ha H, Kim W-H, et al. Phenomenological examinations of delirium in advanced cancer patients: exploratory structural equation modelling and latent profile analysis. BMC Palliative Care. 2020;19:162.","journal-title":"BMC Palliative Care"},{"key":"987_CR3","doi-asserted-by":"crossref","unstructured":"Mercadante S, Adile C, Ferrera P, et al. Symptom expression in patients with advanced cancer admitted to an acute supportive\/palliative care unit with and without delirium. The Oncologist 2018; 24: e358-e364.","DOI":"10.1634\/theoncologist.2018-0244"},{"key":"987_CR4","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1001\/jama.2010.1013","volume":"304","author":"J Witlox","year":"2010","unstructured":"Witlox J, Eurelings LS, de Jonghe JF, et al. Delirium in elderly patients and the risk of postdischarge mortality, institutionalization, and dementia: a meta-analysis. JAMA. 2010;304:443\u201351.","journal-title":"JAMA"},{"key":"987_CR5","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Richardson SJ, Davis DHJ, Stephan BCM, et al. Recurrent delirium over 12 months predicts dementia: results of the Delirium and Cognitive Impact in Dementia (DECIDE) study. Age Ageing 2021; 50: 914-920. Important study demonstrating the link with delirium and dementia.","DOI":"10.1093\/ageing\/afaa244"},{"key":"987_CR6","doi-asserted-by":"crossref","unstructured":"Agar MR, Quinn SJ, Crawford GB, et al. Predictors of mortality for delirium in palliative care. J Palliat Med 2016; 19: 1205-1209. 2016\/06\/17.","DOI":"10.1089\/jpm.2015.0416"},{"issue":"5","key":"987_CR7","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1002\/1097-0142(20000901)89:5<1145::AID-CNCR24>3.0.CO;2-X","volume":"89","author":"A Caraceni","year":"2000","unstructured":"Caraceni A, Nanni O, Maltoni M, et al. Impact of delirium on the short term prognosis of advanced cancer patients. Italian Multicenter Study Group on Palliative Care. Cancer. 2000;89(5):1145\u20139.","journal-title":"Cancer"},{"key":"987_CR8","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1634\/theoncologist.2015-0115","volume":"20","author":"M de la Cruz","year":"2015","unstructured":"de la Cruz M, Ransing V, Yennu S, et al. The frequency, characteristics, and outcomes among cancer patients with delirium admitted to an acute palliative care unit. Oncologist. 2015;20:1425\u201331.","journal-title":"Oncologist"},{"key":"987_CR9","doi-asserted-by":"crossref","unstructured":"Tieges Z, Quinn T, MacKenzie L, et al. Association between components of the delirium syndrome and outcomes in hospitalised adults: a systematic review and meta-analysis. BMC Geriatr 2021; 21: 162. 2021\/03\/07.","DOI":"10.1186\/s12877-021-02095-z"},{"key":"987_CR10","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1002\/cncr.30133","volume":"122","author":"AF Elsayem","year":"2016","unstructured":"Elsayem AF, Bruera E, Valentine AD, et al. Delirium frequency among advanced cancer patients presenting to an emergency department: a prospective, randomized, observational study. Cancer. 2016;122:2918\u201324.","journal-title":"Cancer"},{"key":"987_CR11","doi-asserted-by":"crossref","unstructured":"Bush SH, Lawlor PG, Ryan K, et al. Delirium in adult cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol 2018; 29: iv143-iv165. 2018\/07\/12.","DOI":"10.1093\/annonc\/mdy147"},{"key":"987_CR12","doi-asserted-by":"crossref","unstructured":"\u2022 Jung P, Puts M, Frankel N, et al. Delirium incidence, risk factors, and treatments in older adults receiving chemotherapy: a systematic review and meta-analysis. J Geriatr Oncol 2021; 12: 352-360. Provides insights into the incidence of delirium during cancer treatment.","DOI":"10.1016\/j.jgo.2020.08.011"},{"key":"987_CR13","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1001\/archinte.160.6.786","volume":"160","author":"PG Lawlor","year":"2000","unstructured":"Lawlor PG, Gagnon B, Mancini IL, et al. Occurrence, causes, and outcome of delirium in patients with advanced cancer: a prospective study. Archives of Internal Medicine. 2000;160:786\u201394.","journal-title":"Archives of Internal Medicine"},{"key":"987_CR14","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/cam4.2669","volume":"9","author":"Y Matsuda","year":"2020","unstructured":"Matsuda Y, Maeda I, Morita T, et al. Reversibility of delirium in ill-hospitalized cancer patients: does underlying etiology matter? Cancer Medicine. 2020;9:19\u201326.","journal-title":"Cancer Medicine"},{"key":"987_CR15","doi-asserted-by":"crossref","unstructured":"Sands MB, Wee I, Agar M, et al. The detection of delirium in admitted oncology patients: a scoping review. Eur Geriatr Med 2022.","DOI":"10.1007\/s41999-021-00586-1"},{"key":"987_CR16","unstructured":"\u2022\u2022 Scottish Intercollegiate Guidelines Network (SIGN). Risk reduction and management of delirium. Edinburgh: SIGN; 2019.(SIGN publication no. 157). [March 2019]. Available from URL: http:\/\/www.sign.ac.uk. The most current comprehensive delirium guideline internationally."},{"key":"987_CR17","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1177\/0269216321994730","volume":"35","author":"CL Watt","year":"2021","unstructured":"Watt CL, Scott M, Webber C, et al. Delirium screening tools validated in the context of palliative care: a systematic review. Palliat Med. 2021;35:683\u201396.","journal-title":"Palliat Med"},{"key":"987_CR18","doi-asserted-by":"crossref","unstructured":"Sands MB, Sharma S, Carpenter L, et al. \"SQiD, the Single Question in Delirium; can a single question help clinicians to detect delirium in hospitalised cancer patients?\" running heading Single Question in Delirium\" (Bcan-D-20-01665). BMC Cancer 2021; 21: 75.","DOI":"10.1186\/s12885-020-07504-x"},{"key":"987_CR19","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.mcna.2020.01.006","volume":"104","author":"M Agar","year":"2020","unstructured":"Agar M, Bush S. Delirium at the end of life. Med Clin N Am. 2020;104:491\u2013501.","journal-title":"Med Clin N Am"},{"key":"987_CR20","doi-asserted-by":"crossref","unstructured":"Siddiqi N, Harrison JK, Clegg A, et al. Interventions for preventing delirium in hospitalised non-ICU patients. Cochrane Database of Systematic Reviews (Online) 2016; 3: Cd005563. 2016\/03\/12.","DOI":"10.1002\/14651858.CD005563.pub3"},{"key":"987_CR21","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jamainternmed.2014.7779","volume":"175","author":"TT Hshieh","year":"2015","unstructured":"Hshieh TT, Yue J, Oh E, et al. Effectiveness of multicomponent nonpharmacological delirium interventions: a meta-analysis. JAMA Internal Medicine. 2015;175:512\u201320.","journal-title":"JAMA Internal Medicine"},{"key":"987_CR22","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Mudge AM, McRae P, Banks M, et al. Effect of a ward-based program on hospital-associated complications and length of stay for older inpatients: the cluster randomized CHERISH trial. JAMA Internal Medicine 2022. Evaluated a ward-based program to more consistently implement nonpharmacological care.","DOI":"10.1001\/jamainternmed.2021.7556"},{"key":"987_CR23","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Hosie A, Phillips J, Lam L, et al. A multicomponent nonpharmacological intervention to prevent delirium for hospitalized people with advanced cancer: a phase II cluster randomized waitlist controlled trial (the PRESERVE pilot study). J Palliat Med 2020; 23: 1314-1322. The first study to explore nonpharmacological intervention adherence and feasibility in palliative care settings in depth.","DOI":"10.1089\/jpm.2019.0632"},{"key":"987_CR24","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1093\/ageing\/afq140","volume":"40","author":"A Clegg","year":"2011","unstructured":"Clegg A, Young JB. Which medications to avoid in people at risk of delirium: a systematic review. Age & Ageing. 2011;40:23\u20139.","journal-title":"Age & Ageing"},{"key":"987_CR25","doi-asserted-by":"crossref","unstructured":"\u2022 Sampson EL, West E and Fischer T. Pain and delirium: mechanisms, assessment, and management. European Geriatric Medicine 2020; 11: 45-52. A current review of the complex interaction between pain and delirium.","DOI":"10.1007\/s41999-019-00281-2"},{"key":"987_CR26","unstructured":"National Institute for Health and Clinical Excellence (NICE) National Clinical Guideline centre. Delirium: diagnosis, prevention and management, http:\/\/www.nice.org.uk\/nicemedia\/live\/13060\/49908\/49908.pdf (2010). Accessed 3rd Feb 2022."},{"key":"987_CR27","doi-asserted-by":"crossref","unstructured":"Milisen K, Foreman MD, Abraham IL, et al. A nurse-led interdisciplinary intervention program for delirium in elderly hip-fracture patients. Journal of the American Geriatrics Society;49(5):523-32 2001.","DOI":"10.1046\/j.1532-5415.2001.49109.x"},{"key":"987_CR28","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1093\/gerona\/61.2.176","volume":"61","author":"KH Pitkala","year":"2006","unstructured":"Pitkala KH, Laurila JV, Strandberg TE, et al. Multicomponent geriatric intervention for elderly inpatients with delirium: a randomized, controlled trial. J Gerontol A Biol Sci Med Sci. 2006;61:176\u201381.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"987_CR29","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1136\/bmjspcare-2020-002600","volume":"11","author":"A Kingdon","year":"2021","unstructured":"Kingdon A, Spathis A, Brodrick R, et al. What is the impact of clinically assisted hydration in the last days of life? A systematic literature review and narrative synthesis. BMJ Support Palliat Care. 2021;11:68\u201374.","journal-title":"BMJ Support Palliat Care"},{"key":"987_CR30","unstructured":"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/haldol-associated-names, (2017)."},{"key":"987_CR31","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1177\/0269216319853487","volume":"33","author":"A Hosie","year":"2019","unstructured":"Hosie A, Siddiqi N, Featherstone I, et al. Inclusion, characteristics and outcomes of people requiring palliative care in studies of non-pharmacological interventions for delirium: a systematic review. Palliat Med. 2019;33:878\u201399.","journal-title":"Palliat Med"},{"key":"987_CR32","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1093\/ageing\/afz171","volume":"49","author":"MR Agar","year":"2020","unstructured":"Agar MR. Delirium at the end of life. Age and Ageing. 2020;49:337\u201340.","journal-title":"Age and Ageing"},{"key":"987_CR33","doi-asserted-by":"publisher","unstructured":"Neufeld KJ, Yue J, Robinson TN, et al. Antipsychotic medication for prevention and treatment of delirium in hospitalized adults: a systematic review and meta-analysis. J Am Geriatr Soc 2016 2016\/03\/24. https:\/\/doi.org\/10.1111\/jgs.14076.","DOI":"10.1111\/jgs.14076"},{"key":"987_CR34","doi-asserted-by":"crossref","unstructured":"Burry L, Mehta S, Perreault MM, et al. Antipsychotics for treatment of delirium in hospitalised non-ICU patients. Cochrane Database of Systematic Reviews (Online) 2018; 6: Cd005594.","DOI":"10.1002\/14651858.CD005594.pub3"},{"key":"987_CR35","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1056\/NEJMoa1808217","volume":"379","author":"TD Girard","year":"2018","unstructured":"Girard TD, Exline MC, Carson SS, et al. Haloperidol and ziprasidone for treatment of delirium in critical illness. N Engl J Med. 2018;379:2506\u201316.","journal-title":"N Engl J Med"},{"key":"987_CR36","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1001\/jamainternmed.2016.7491","volume":"177","author":"MR Agar","year":"2017","unstructured":"Agar MR, Lawlor PG, Quinn S, et al. Efficacy of oral risperidone, haloperidol, or placebo for symptoms of delirium among patients in palliative care: a randomized clinical trial. JAMA Internal Medicine. 2017;177:34\u201342.","journal-title":"JAMA Internal Medicine"},{"key":"987_CR37","doi-asserted-by":"crossref","unstructured":"Hui D, Frisbee-Hume S, Wilson A, et al. Effect of lorazepam with haloperidol vs haloperidol alone on agitated delirium in patients with advanced cancer receiving palliative care: a randomized clinical trial. JAMA 2017; 318: 1047-1056. 2.","DOI":"10.1001\/jama.2017.11468"},{"key":"987_CR38","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/S1470-2045(20)30307-7","volume":"21","author":"D Hui","year":"2020","unstructured":"Hui D, De La Rosa A, Wilson A, et al. Neuroleptic strategies for terminal agitation in patients with cancer and delirium at an acute palliative care unit: a single-centre, double-blind, parallel-group, randomised trial. Lancet Oncol. 2020;21:989\u201398.","journal-title":"Lancet Oncol"},{"key":"987_CR39","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1001\/jama.294.15.1934","volume":"294","author":"LS Schneider","year":"2005","unstructured":"Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294:1934\u201343.","journal-title":"JAMA"},{"key":"987_CR40","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jpsychires.2020.12.020","volume":"133","author":"K Khaing","year":"2021","unstructured":"Khaing K, Nair BR. Melatonin for delirium prevention in hospitalized patients: a systematic review and meta-analysis. J Psychiatr Res. 2021;133:181\u201390.","journal-title":"J Psychiatr Res"},{"key":"987_CR41","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s12904-020-00669-z","volume":"19","author":"PG Lawlor","year":"2020","unstructured":"Lawlor PG, McNamara-Kilian MT, MacDonald AR, et al. Melatonin to prevent delirium in patients with advanced cancer: a double blind, parallel, randomized, controlled, feasibility trial. BMC Palliative Care. 2020;19:163. https:\/\/doi.org\/10.1186\/s12904-020-00669-z.","journal-title":"BMC Palliative Care"},{"key":"987_CR42","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.bja.2017.11.001","volume":"120","author":"J Freeman","year":"2018","unstructured":"Freeman J, Buggy DJ. Modelling the effects of perioperative interventions on cancer outcome: lessons from dexmedetomidine. Br J Anaesth. 2018;120:15\u20137.","journal-title":"Br J Anaesth"},{"key":"987_CR43","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.bja.2017.11.004","volume":"120","author":"H Lavon","year":"2018","unstructured":"Lavon H, Matzner P, Benbenishty A, et al. Dexmedetomidine promotes metastasis in rodent models of breast, lung, and colon cancers. Br J Anaesth. 2018;120:188\u201396.","journal-title":"Br J Anaesth"},{"key":"987_CR44","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1177\/0269216321994440","volume":"35","author":"B Thomas","year":"2021","unstructured":"Thomas B, Lo WA, Nangati Z, et al. Dexmedetomidine for hyperactive delirium at the end of life: an open-label single arm pilot study with dose escalation in adult patients admitted to an inpatient palliative care unit. Palliat Med. 2021;35:729\u201337.","journal-title":"Palliat Med"},{"key":"987_CR45","doi-asserted-by":"crossref","unstructured":"Traube C, Ariagno S, Thau F, et al. Delirium in hospitalized children with cancer: incidence and associated risk factors. J Pediatr 2017; 191: 212-217. 2017\/11\/28.","DOI":"10.1016\/j.jpeds.2017.08.038"},{"key":"987_CR46","doi-asserted-by":"crossref","unstructured":"Turkel SB. Pediatric delirium: recognition, management, and outcome. Curr Psychiatry Rep. 2017;19.","DOI":"10.1007\/s11920-017-0851-1"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-022-00987-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-022-00987-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-022-00987-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T16:23:21Z","timestamp":1654619001000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-022-00987-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,11]]},"references-count":46,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["987"],"URL":"https:\/\/doi.org\/10.1007\/s11864-022-00987-9","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,11]]},"assertion":[{"value":"6 April 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All reported studies\/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional\/national research committee standards, and international\/national\/institutional guidelines).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"Meera R. Agar has received research funding through a grant from Cancer Australia and the National Breast Cancer Foundation for delirium intervention clinical trials; has received a speaker\u2019s honorarium from AstraZeneca for presenting at the Clinical Oncological Society of Australia Annual Scientific Meeting; and is a Board Member of the European Delirium Association. Ingrid Amgarth-Duff declares that she has no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}